BusinessRadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212By Nasdaq OMXNov 1, 2016, 5:00 AM UTC
BusinessKura Oncology to Report Third Quarter 2016 Financial ResultsBy Nasdaq OMXOct 31, 2016, 8:05 PM UTC
BusinessStudy Shows First Practical Intervention For ChemobrainBy Nasdaq OMXOct 31, 2016, 8:00 PM UTC
BusinessKura Oncology to Participate in the 9th European Scientific Oncology ConferenceBy Nasdaq OMXOct 31, 2016, 11:30 AM UTC
BusinessPetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health PipelineBy Nasdaq OMXOct 27, 2016, 2:30 PM UTC
BusinessPetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of DirectorsBy Nasdaq OMXOct 24, 2016, 4:00 PM UTC
BusinessRadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)By Nasdaq OMXOct 20, 2016, 6:30 AM UTC
BusinessPetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company WebsiteBy Nasdaq OMXOct 17, 2016, 12:01 PM UTC
